Skip to main content
Premium Trial:

Request an Annual Quote

NantHealth, TransMed Systems Team to Provide Clinicians With Cancer Data

NEW YORK (GenomeWeb) – NantHealth announced today that it has signed a partnership agreement with software developer TransMed Systems to provide cancer centers in the US with data that can help clinicians improve patient outcomes and speed cancer research.

NantHealth said the deal is an operational milestone of the QUILT (Quantum Immuno-oncology Lifelong Trial) program — an initiative of NantHealth Founder and CEO Patrick Soon-Shiong's Cancer Moonshot 2020 designed to test novel combinations of vaccines, cell-based immunotherapy, metronomic chemotherapy, low-dose radiotherapy, and immunomodulators in patients who have undergone next-generation whole-genome, transcriptome, and quantitative proteomic analysis.

The two companies will disseminate the data over the next year to cancer centers through the websites of the Quality Cancer Care Alliance and the National Cancer Care Alliance.

Further terms of the deal were not disclosed.

NantHealth's GPS Cancer, which the company began selling in June 2016, integrates quantitative proteomics with whole-genome and transcriptome sequencing data. It provides oncologists with a comprehensive molecular profile of a patient's cancer to inform personalized treatment strategies, including choice of chemotherapy. TransMed's Clinical Practice Suite provides clinicians with applications that identify treatment options and historical outcomes for patients similar to their own.

"We are thrilled to join forces with TransMed to provide community oncologists with access to data to support their efforts and understand the underlying mechanisms of cancer," Soon-Shiong said in a statement. "Oncologists throughout the country are constantly searching for trials that fit their specific patients' needs. This initiative creates the opportunity for patients to access new and existing trials under the QUILT program."

Also this week, NantHealth signed two separate deals to distribute GPS Cancer in the Middle East — one with Lunatus for the United Arab Emirates, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon, and the other with Teva Pharmaceuticals subsidiary Oncotest-Teva for Israel.

Filed under